BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a respiratory disorder with increasing prevalence and mortality. It is associated with airway obstruction, increased airway hyper-responsiveness (AHR), and ongoing airway and lung inflammation dominated by CD8 lymphocytes and neutrophils. Single-nucleotide polymorphisms (SNPs) in a disintegrin and metalloprotease 33 (ADAM33) gene have been associated with AHR and COPD. OBJECTIVE: To assess whether SNPs in ADAM33 are associated with the severity of AHR and airway inflammation in COPD. METHODS: Eight SNPs in ADAM33 (F+1, Q-1, S_1, S_2, ST+5, T_1, T_2, V_4) were genotyped in 111 patients with COPD (96 males, 69 current smokers, mean (standard deviation (SD)), aged 62 (8) years, median pack-years 42 (IQR 31-55), mean postbronchodilator forced expiratory volume in 1 s (FEV(1))% predicted 63 (9). Provocative concentration of methacholine causing a decrease in FEV(1) of 20% (PC(20) methacholine), sputum and bronchial biopsies were collected. RESULTS: Patients with the ST+5 AA genotype had more severe AHR, higher numbers of sputum inflammatory cells and CD8 cells in bronchial biopsies than patients with the GG genotype (p = 0.03, 0.05 and 0.01, respectively). CD8 cell numbers were lower in patients carrying the minor allele of SNP T_1 and T_2, and homozygotic minor variants of SNP S_2 compared with the wild type (p = 0.02, 0.01 and 0.02, respectively). CONCLUSIONS: This is the first study revealing that SNPs in a gene that confers susceptibility to COPD in the general population-that is, ADAM33-are associated with AHR and airway inflammation in COPD. These findings constitute an important step forward in linking gene polymorphisms with COPD pathophysiology, thereby possibly contributing to better treatments for this progressive and disabling disease in the future.
BACKGROUND:Chronic obstructive pulmonary disease (COPD) is a respiratory disorder with increasing prevalence and mortality. It is associated with airway obstruction, increased airway hyper-responsiveness (AHR), and ongoing airway and lung inflammation dominated by CD8 lymphocytes and neutrophils. Single-nucleotide polymorphisms (SNPs) in a disintegrin and metalloprotease 33 (ADAM33) gene have been associated with AHR and COPD. OBJECTIVE: To assess whether SNPs in ADAM33 are associated with the severity of AHR and airway inflammation in COPD. METHODS: Eight SNPs in ADAM33 (F+1, Q-1, S_1, S_2, ST+5, T_1, T_2, V_4) were genotyped in 111 patients with COPD (96 males, 69 current smokers, mean (standard deviation (SD)), aged 62 (8) years, median pack-years 42 (IQR 31-55), mean postbronchodilator forced expiratory volume in 1 s (FEV(1))% predicted 63 (9). Provocative concentration of methacholine causing a decrease in FEV(1) of 20% (PC(20) methacholine), sputum and bronchial biopsies were collected. RESULTS:Patients with the ST+5 AA genotype had more severe AHR, higher numbers of sputum inflammatory cells and CD8 cells in bronchial biopsies than patients with the GG genotype (p = 0.03, 0.05 and 0.01, respectively). CD8 cell numbers were lower in patients carrying the minor allele of SNP T_1 and T_2, and homozygotic minor variants of SNP S_2 compared with the wild type (p = 0.02, 0.01 and 0.02, respectively). CONCLUSIONS: This is the first study revealing that SNPs in a gene that confers susceptibility to COPD in the general population-that is, ADAM33-are associated with AHR and airway inflammation in COPD. These findings constitute an important step forward in linking gene polymorphisms with COPD pathophysiology, thereby possibly contributing to better treatments for this progressive and disabling disease in the future.
Authors: Donna E Davies; James Wicks; Robert M Powell; Sarah M Puddicombe; Stephen T Holgate Journal: J Allergy Clin Immunol Date: 2003-02 Impact factor: 10.793
Authors: Charles G Garlisi; Jun Zou; Kristine E Devito; Fang Tian; Feng X Zhu; Jianjun Liu; Himanshu Shah; Yuntao Wan; M Motasim Billah; Robert W Egan; Shelby P Umland Journal: Biochem Biophys Res Commun Date: 2003-01-31 Impact factor: 3.575
Authors: Denise L Lind; Shweta Choudhry; Ngim Ung; Elad Ziv; Pedro C Avila; Keyan Salari; Connie Ha; Elizabeth G Lovins; Natasha E Coyle; Sylvette Nazario; Jesus Casal; Alfonso Torres; Jose R Rodriguez-Santana; Henry Matallana; Craig M Lilly; Jorge Salas; Moises Selman; Homer A Boushey; Scott T Weiss; Rocio Chapela; Jean G Ford; William Rodriguez-Cintron; Edwin K Silverman; Dean Sheppard; Pui-Yan Kwok; Esteban González Burchard Journal: Am J Respir Crit Care Med Date: 2003-09-04 Impact factor: 21.405
Authors: H Jongepier; H M Boezen; A Dijkstra; T D Howard; J M Vonk; G H Koppelman; S L Zheng; D A Meyers; E R Bleecker; D S Postma Journal: Clin Exp Allergy Date: 2004-05 Impact factor: 5.018
Authors: B W M Willemse; N H T ten Hacken; B Rutgers; I G A T Lesman-Leegte; W Timens; D S Postma Journal: Eur Respir J Date: 2004-09 Impact factor: 16.671
Authors: Shelby P Umland; Charles G Garlisi; Himanshu Shah; Yuntao Wan; Jun Zou; Kristine E Devito; Whei-Mei Huang; Eric L Gustafson; Robert Ralston Journal: Am J Respir Cell Mol Biol Date: 2003-05-30 Impact factor: 6.914
Authors: Thérèse S Lapperre; Jiska B Snoeck-Stroband; Margot M E Gosman; Jan Stolk; Jaap K Sont; Désirée F Jansen; Huib A M Kerstjens; Dirkje S Postma; Peter J Sterk Journal: Am J Respir Crit Care Med Date: 2004-06-01 Impact factor: 21.405
Authors: Antoon Dijkstra; Dirkje S Postma; Jacobien A Noordhoek; Monique E Lodewijk; Henk F Kauffman; Nick H T ten Hacken; Wim Timens Journal: Virchows Arch Date: 2009-03-03 Impact factor: 4.064
Authors: Adel Boueiz; Sharon M Lutz; Michael H Cho; Craig P Hersh; Russell P Bowler; George R Washko; Eitan Halper-Stromberg; Per Bakke; Amund Gulsvik; Nan M Laird; Terri H Beaty; Harvey O Coxson; James D Crapo; Edwin K Silverman; Peter J Castaldi; Dawn L DeMeo Journal: Am J Respir Crit Care Med Date: 2017-03-15 Impact factor: 21.405
Authors: Simona E Budulac; Dirkje S Postma; Pieter S Hiemstra; Lisette I Z Kunz; Mateusz Siedlinski; Henriette A Smit; Judith M Vonk; Bea Rutgers; Wim Timens; H Marike Boezen Journal: Respir Res Date: 2010-05-20